A straightforward way to get real-world dataBuilding the fact base for your research needs

Real-world data (RWD) is anonymous patient-level data, which is increasingly available butcomplex and not always perfect. IMS Health is committed to helping you access the best datanetworks for your research needs

• Largest international fit-for-purpose RWD portfolio, with 500+ million records

• Ability to supplement IMS Health, client and other third-party data

• Sourcing expertise to find, access and curate new data sources to support deeper research

We ensure RWD that you can use with confidenceThe reality of RWD is that with all its potential to provide unique patient insights it is complex,unstructured and often has quality issues.

We help you build a fact base with robust data, sourced and cleaned to enable confident applicationfor scientific and commercial purposes.

And we ensure that quality management and patient privacy are never compromised.

IMS Health Real-World Data

IMS Health Real-World Evidence SolutionsREAL-WORLD DATA

Our Real-World Evidence Solutions (RWE) team takes a credible, user-friendly approach to bring youthe right patient-level data, complemented by the technology, analytical and medical, scientific &safety expertise to generate and interpret the RWE you need.

Disease and Therapy Area Depth

Coverage of nearly every disease,

including very rare conditions and supplement as needed, with extra investments alreadymade in oncology and diabetes.

Geographic Breadth

Anonymous patient-level data

on 500+m patientsacross 25+ countrieswith access to our

network of data providers in 50+ markets.

Type of Data

10+data types withmodifications to methodology as required, determination of'best use' alone or combinedwith other data – and ability toidentify new data types as well.

The Three Dimensions of IMS Health Real-World Data

We give you access to the RWD your research needs

ORB01139A RWD Summary 4pp Factsheet_Layout 1 26/10/2015 07:44 Page 1

A straightforward way to get real-world data Page 2

Putting the ‘T’ in RWDT-shaped Evidence Networks reflect the need to consider both breadth and depth when accessing themost appropriate fact base.

IMS Health RWD portfolioAccess to patient-level data around the world

Electronic Medical Records (EMR)Australia, Belgium, Canada, France,Germany, Italy, New Zealand, Portugal,Spain, UK, USA

Integrated EMR (Pygargus) Denmark, Norway, Sweden

Adjudicated ClaimsCanada (Payer – drug plans)UAE (All sites)USA (Payer – all sites)

Pre-adjudicated Claims UAE (Payer – all sites)USA (Medical)

HospitalBelgium, Netherlands, Portugal, UK, USA

Lab Results/Consumer/Behavioral USA

Longitudinal Prescriptions (LRx) Australia, Belgium, Canada, France,Germany, Hungary, Italy, Japan,Netherlands, Poland, Spain,Switzerland, UK, USA

IMS RWD Therapy Area Assets

Diabetes Enriched EMRFrance, Germany

Oncology EMRUSA

Oncology Cross-sectional SurveyBelgium, Canada, China, France,Germany, Italy, Japan, South Korea,Netherlands, Russia, Spain, Taiwan,Turkey, UAE, UK

Hospital Claims/DischargePMSI (France), MDV (Japan),HES (UK)

Database NetworkPharmo (Netherlands)

Electronic Medical Records (EMR)SIDIAP (Catalonia, Spain), CPRD (UK)

Integrated RecordsCPRD (UK), HTI-CPRD (UK)

RegistriesNordic Registry (Denmark, Finland,Iceland, Norway, Sweden)

BiobankNorway

Examples of IMS Health as licensedoperator or collaboration partner

Rang

e of

dat

a ty

pes

Deep, flexibletherapy-area-specific data

To create complete disease views, we usesophisticated approaches to supplement data,including: eCRF, ePRO, NLP and rapid customsourcing/linkage

DEEP

BROADNationally relevant databases

Augmented datasets

Population coverage

Biobanks, labs, registries

• RWD sources spanning broad, near population-level cohorts but with limited clinical informationabout each patient

• Clinically rich, deep data for a discrete population of patients, typically with coverage of 5-10% of atotal market population

Ask us about our innovative approaches to enabling clients to build out their own T-shaped networks.

ORB01139A RWD Summary 4pp Factsheet_Layout 1 26/10/2015 07:44 Page 2

A straightforward way to get real-world data Page 3

Enriching existing datasetsData linkage

• Understanding the full patient pathway through integrating datasets at the record level (eg, IMS RWD integrated offerings in the USA, Pygargus methodology in Scandinavia)

Strategic data sourcing

• Enhancing IMS RWD to generate complete patient views through custom sourcing support (eg, eCRF, ePRO, NLP) and rapid custom sourcing to extract data and create custom datasets

• Identify and access new data sources addressing specific research needs, also in niche markets

1

2

Replication of RCT data using IMS RWD EMRUsed fit-for-purpose EMR data to replicate an analysis of six randomized clinical trials (RCTs). EMR data provided

5,535 patients to compare

to 411 in the RCTs

Linkage of IMS RWD Diabetes with client data

Integrated client RCT with multiple IMS RWD assets to support

pragmatic trials

Integration of IMS RWD Claims and EMR with newly sourced dataIdentified and sourced new MRI data for client and digitized/curated this forintegration with existing data mart to documenttreatment progression

Analysis of IMS RWD Claims–US

to support product value

Analyzed IMS RWD Claims–US to show value of a branded product

versus generics of a competing molecule for specific patient profile

3

4

Start with the right fact base - four case examples

Multi-country RWDWith EMR data available in 11 countries, LRx data in 14 countries across 4 continents, and oncologysurvey data from more than 250,000 patients per year covering more than 25 tumor types, IMS Health is uniquely positioned to run multi-country RWD studies.

GlobalMarket

Research

• Market opportunity assessments• Event-based forecasts• Launch tracking, KPIs

Custom studies in support of regulatory filings, eg, • Burden of illness• Value dossiers• Compliance & persistence studies• Pharmacoepidemiology & drug safety

HEORRegulatory

Affairs

ORB01139A RWD Summary 4pp Factsheet_Layout 1 26/10/2015 07:44 Page 3

©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

ORB01139A-1115

Metastatic melanoma market example

RWD provides clarity not previously possible

What looking at marketshare shows

What looking at treatment patterns reveals

Source: IMS RWD Oncology EMR–US (2013)

60%

50%

40%

30%

20%

10%

0%

1st line therapy~75% of tx pts

2nd+ line therapy~25% of tx pts

Mar-12

May-12

Jul-1

2

Sep-12

Nov-12

Jan-13

Mar-13

60%

50%

40%

30%

20%

10%

0%

Mar-12

May-12

Jul-1

2

Sep-12

Nov-12

Jan-13

Mar-13

60%

50%

40%

30%

20%

10%

0%

Mar-12

May-12

Jul-1

2

Sep-12

Nov-12

Jan-13

Mar-13

Product A Product B Product C All Other

USA +1 (484) 567 6461 • One IMS Drive, Plymouth Meeting, Pennsylvania 19462, USA.Europe +44 (0) 20 3075 4800 • 210 Pentonville Road, London N1 9JY, UK.Asia Pacific +65 6412 7365 • Latin America +52 55 5089 5205 • RWEinfo@imshealth.com • www.imshealth.com/rwe

IMS Health Real-World Evidence SolutionsUncovering insights from real-world data to improve decisionmaking and patient outcomes

Technology-EnabledAnalyticsReal-World

Data

Services and

Engagement

IMS HEALTHREAL-WORLD

EVIDENCESOLUTIONS

Acce

ss th

e ri

ght r

eal-w

orld

dat

a

Analyze the data

Create datasets

Apply the insights

ORB01139A RWD Summary 4pp Factsheet_Layout 1 26/10/2015 07:44 Page 4